Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit
Background: Intraperitoneal chemotherapy using paclitaxel (i.p.-PTX) is expected to be a new therapeutic strategy for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal dissemination. We evaluated the survival benefit of i.p.-PTX compared with standard systemic chemotherapy. Method...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/5/1354 |
| _version_ | 1797475424228343808 |
|---|---|
| author | Tomohisa Yamamoto Sohei Satoi So Yamaki Daisuke Hashimoto Mitsuaki Ishida Tsukasa Ikeura Satoshi Hirooka Yuki Matsui Shogen Boku Shinji Nakayama Koh Nakamaru Nobuhiro Shibata Utae Katsushima Mitsugu Sekimoto |
| author_facet | Tomohisa Yamamoto Sohei Satoi So Yamaki Daisuke Hashimoto Mitsuaki Ishida Tsukasa Ikeura Satoshi Hirooka Yuki Matsui Shogen Boku Shinji Nakayama Koh Nakamaru Nobuhiro Shibata Utae Katsushima Mitsugu Sekimoto |
| author_sort | Tomohisa Yamamoto |
| collection | DOAJ |
| description | Background: Intraperitoneal chemotherapy using paclitaxel (i.p.-PTX) is expected to be a new therapeutic strategy for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal dissemination. We evaluated the survival benefit of i.p.-PTX compared with standard systemic chemotherapy. Methods: Clinical data of 101 consecutive PDAC patients with peritoneal dissemination between 2007 and 2018 were analyzed. All patients were determined to have no other sites of distant organ metastasis to the lung, bone, or liver on contrast-enhanced CT imaging. Patients underwent staging laparoscopy or open laparotomy to confirm pathological evidence of peritoneal dissemination, and to exclude occult liver metastasis. Survival curves were estimated using the Kaplan–Meier method, and differences were compared using the log-rank test. Results: Forty-three patients were treated with i.p.-PTX (i.p.-PTX group) and forty-nine patients received standard systemic chemotherapy (Ctrl group). Nine patients did not receive any treatment (BSC group). The median survival time (MST) in the i.p.-PTX group was significantly longer than that in the Ctrl group (17.9 months vs. 10.2 months, <i>p</i> = 0.006). Negative peritoneal washing cytology was observed in 24 out of 43 patients in the i.p.-PTX group. The i.p.-PTX group tended to have a higher proportion of clinical responses than the Ctrl group (30% vs. 18%, <i>p</i> = 0.183). Conversion surgery was performed in 10 patients in the i.p.-PTX group and 2 patients in the Ctrl group after confirming disappearance of peritoneal dissemination with staging laparoscopy or open laparotomy (<i>p</i> = 0.005). The MST in patients who underwent surgical resection was significantly longer than that in patients who did not (27.4 months vs. 11.3 months; <i>p</i> < 0.0001). Conclusion: i.p.-PTX therapy provided improved survival in PDAC patients with peritoneal dissemination, and conversion surgery enhanced it in patients with favorable responses to chemotherapy. i.p.-PTX might become one of the treatment options to PDAC patients with peritoneal dissemination. |
| first_indexed | 2024-03-09T20:44:54Z |
| format | Article |
| id | doaj.art-9b1dcee4e67c4d05971f507259f2eaa3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:44:54Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9b1dcee4e67c4d05971f507259f2eaa32023-11-23T22:49:42ZengMDPI AGCancers2072-66942022-03-01145135410.3390/cancers14051354Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival BenefitTomohisa Yamamoto0Sohei Satoi1So Yamaki2Daisuke Hashimoto3Mitsuaki Ishida4Tsukasa Ikeura5Satoshi Hirooka6Yuki Matsui7Shogen Boku8Shinji Nakayama9Koh Nakamaru10Nobuhiro Shibata11Utae Katsushima12Mitsugu Sekimoto13Department of Surgery, Kansai Medical University, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanDepartment of Pathology and Clinical Laboratory, Kansai Medical University, Osaka 573-1010, JapanThe Third Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanCancer Treatment Center, Kansai Medical University Hospital, Osaka 573-1010, JapanThe Third Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, JapanThe Third Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, JapanCancer Treatment Center, Kansai Medical University Hospital, Osaka 573-1010, JapanDepartment of Physical Medicine and Rehabilitation, Kansai Medical University Hospital, Osaka 573-1010, JapanDepartment of Surgery, Kansai Medical University, Osaka 573-1010, JapanBackground: Intraperitoneal chemotherapy using paclitaxel (i.p.-PTX) is expected to be a new therapeutic strategy for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal dissemination. We evaluated the survival benefit of i.p.-PTX compared with standard systemic chemotherapy. Methods: Clinical data of 101 consecutive PDAC patients with peritoneal dissemination between 2007 and 2018 were analyzed. All patients were determined to have no other sites of distant organ metastasis to the lung, bone, or liver on contrast-enhanced CT imaging. Patients underwent staging laparoscopy or open laparotomy to confirm pathological evidence of peritoneal dissemination, and to exclude occult liver metastasis. Survival curves were estimated using the Kaplan–Meier method, and differences were compared using the log-rank test. Results: Forty-three patients were treated with i.p.-PTX (i.p.-PTX group) and forty-nine patients received standard systemic chemotherapy (Ctrl group). Nine patients did not receive any treatment (BSC group). The median survival time (MST) in the i.p.-PTX group was significantly longer than that in the Ctrl group (17.9 months vs. 10.2 months, <i>p</i> = 0.006). Negative peritoneal washing cytology was observed in 24 out of 43 patients in the i.p.-PTX group. The i.p.-PTX group tended to have a higher proportion of clinical responses than the Ctrl group (30% vs. 18%, <i>p</i> = 0.183). Conversion surgery was performed in 10 patients in the i.p.-PTX group and 2 patients in the Ctrl group after confirming disappearance of peritoneal dissemination with staging laparoscopy or open laparotomy (<i>p</i> = 0.005). The MST in patients who underwent surgical resection was significantly longer than that in patients who did not (27.4 months vs. 11.3 months; <i>p</i> < 0.0001). Conclusion: i.p.-PTX therapy provided improved survival in PDAC patients with peritoneal dissemination, and conversion surgery enhanced it in patients with favorable responses to chemotherapy. i.p.-PTX might become one of the treatment options to PDAC patients with peritoneal dissemination.https://www.mdpi.com/2072-6694/14/5/1354pancreatic cancerperitoneal disseminationintraperitoneal therapypaclitaxel |
| spellingShingle | Tomohisa Yamamoto Sohei Satoi So Yamaki Daisuke Hashimoto Mitsuaki Ishida Tsukasa Ikeura Satoshi Hirooka Yuki Matsui Shogen Boku Shinji Nakayama Koh Nakamaru Nobuhiro Shibata Utae Katsushima Mitsugu Sekimoto Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit Cancers pancreatic cancer peritoneal dissemination intraperitoneal therapy paclitaxel |
| title | Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit |
| title_full | Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit |
| title_fullStr | Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit |
| title_full_unstemmed | Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit |
| title_short | Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit |
| title_sort | intraperitoneal paclitaxel treatment for patients with pancreatic ductal adenocarcinoma with peritoneal dissemination provides a survival benefit |
| topic | pancreatic cancer peritoneal dissemination intraperitoneal therapy paclitaxel |
| url | https://www.mdpi.com/2072-6694/14/5/1354 |
| work_keys_str_mv | AT tomohisayamamoto intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT soheisatoi intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT soyamaki intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT daisukehashimoto intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT mitsuakiishida intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT tsukasaikeura intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT satoshihirooka intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT yukimatsui intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT shogenboku intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT shinjinakayama intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT kohnakamaru intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT nobuhiroshibata intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT utaekatsushima intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit AT mitsugusekimoto intraperitonealpaclitaxeltreatmentforpatientswithpancreaticductaladenocarcinomawithperitonealdisseminationprovidesasurvivalbenefit |